Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

34 35 Next >

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

May 17, 2023

From MindMed

Via Business Wire

FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120' ↗

May 16, 2023

Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again.

Via Benzinga

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

May 15, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

Mind Medicine: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Earnings Outlook For Mind Medicine ↗

May 03, 2023

Via Benzinga

MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections ↗

May 05, 2023

Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business...

Via Benzinga

FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction

May 05, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed Reports First Quarter 2023 Financial Results and Business Highlights

May 04, 2023

From MindMed

Via Business Wire

MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

May 02, 2023

From MindMed

Via Business Wire

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗

May 01, 2023

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Via Benzinga

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

May 01, 2023

From Mind Medicine (MindMed) Inc.

Via Business Wire

3 High-Growth Penny Stocks to Consider Buying in April 2023 ↗

May 01, 2023

Here are three high-growth penny stocks long-term investors may want to keep on their watch list, or buy, in April.

Via InvestorPlace

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management ↗

April 26, 2023

In this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ: MNMD), Robert Barrow.

Via Benzinga

MindMed to Participate in May Investor Conferences

April 26, 2023

From MindMed

Via Business Wire

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

April 21, 2023

Via Benzinga

FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value

April 21, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗

April 20, 2023

Via Benzinga

Cybin, Mind Medicine Among Top Psychedelic Movers Of Today ↗

April 19, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 18, 2023 ↗

April 18, 2023

Via Benzinga

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

April 18, 2023

From MindMed

Via Business Wire

Psychedelic Stock Gainers And Losers From April 17, 2023 ↗

April 17, 2023

Via Benzinga

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More ↗

April 17, 2023

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

Via Benzinga

80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial ↗

April 17, 2023

Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive...

Via Benzinga

ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

April 14, 2023

Via Benzinga

Why Is Ocugen (OCGN) Stock Moving Today? ↗

April 14, 2023

Ocugen (OCGN) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial.

Via InvestorPlace

Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 14, 2023

Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.

Via Benzinga

US Stocks Mixed; Retail Sales Drop 1% In March ↗

April 14, 2023

U.S. stocks traded mixed this morning, following the release of economic reports. Following the market opening Friday, the Dow traded up 0.08% to 34,055.40 while the NASDAQ fell 0.10% to 12,153.84. The...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.